What false-negative rates of non-invasive testing are active surveillance patients and uro-oncologists willing to accept in order to avoid prostate biopsy?
Can Urol Assoc J. 2017 Mar-Apr;11(3-4):118-122
Science. 2017 Apr 28;356(6336):418-422
Urol Oncol. 2017 Jan 03;:
Development and External Validation of a Biopsy-Derived Nomogram to Predict Risk of Ipsilateral Extraprostatic Extension.
BJU Int. 2016 Dec 08;:
A Phase II, Randomized, Open Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy.
Clin Cancer Res. 2016 Oct 18;:
Limitations in predicting organ-confined prostate cancer in patients with Gleason pattern 4 on biopsy: Implications for active surveillance.
J Urol. 2016 Jul 22;
Efficient generation of patient-matched malignant and normal primary cell cultures from clear cell renal cell carcinoma patients: clinically relevant models for research and personalized medicine.
BMC Cancer. 2016;16:485
Stricter active surveillance criteria for prostate cancer do not result in significantly better outcomes: A comparison of contemporary protocols.
J Urol. 2016 Jun 24;
Cancer stem cells are underestimated by standard experimental methods in clear cell renal cell carcinoma.
Sci Rep. 2016;6:25220
Nanoscale. 2016 Mar 22;